ArticleBehavioural brain research2017
The chemotherapeutic agent paclitaxel selectively impairs learning while sparing source memory and spatial memory.
Article in Behavioural brain research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Effects of chemotherapy on cognitive and physical effort-based decision-making tasks in rats.Psychopharmacology · 2026Article
- Paclitaxel-induced adverse effects: insights into multi-organ toxicities and molecular mechanisms.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Deciphering transcriptomic changes in chemobrain: a comprehensive review.Acta neuropathologica communications · 2025Review
- Validation of a rodent model of episodic memory replay.Learning & behavior · 2025Article
- Paclitaxel-induced cognitive impairment: mechanistic insights.Frontiers in pharmacology · 2025Review
- Effect of vitamin E on doxorubicin and paclitaxel-induced memory impairments in male rats.Cancer chemotherapy and pharmacology · 2024Article
- Cancer related cognitive impairment: a downside of cancer treatment.Frontiers in oncology · 2024Review
- Microglia are implicated in the development of paclitaxel chemotherapy-associated cognitive impairment in female mice.Brain, behavior, and immunity · 2023Article
- Review
- Inhaled Cannabis Suppresses Chemotherapy-Induced Neuropathic Nociception by Decoupling the Raphe Nucleus: A Functional Imaging Study in Rats.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2021Article
- Article
- Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.The Journal of pharmacology and experimental therapeutics · 2018Article
- Cognitive impairment in a rat model of neuropathic pain: role of hippocampal microtubule stability.Pain · 2018Article
- Proinflammatory Factors Mediate Paclitaxel-Induced Impairment of Learning and Memory.Mediators of inflammation · 2018Article
- A test of the reward-contrast hypothesis.Behavioural processes · 2017Article
- The chemotherapeutic agent paclitaxel selectively impairs reversal learning while sparing prior learning, new learning and episodic memory.Neurobiology of learning and memory · 2017Article
- A novel preventive therapy for paclitaxel-induced cognitive deficits: preclinical evidence from C57BL/6 mice.Translational psychiatry · 2017Article
- Voluntary exercise reduces both chemotherapy-induced neuropathic nociception and deficits in hippocampal cellular proliferation in a mouse model of paclitaxel-induced peripheral neuropathy.Neurobiology of pain (Cambridge, Mass.)Article
- Alterations in brain neurocircuitry following treatment with the chemotherapeutic agent paclitaxel in rats.Neurobiology of pain (Cambridge, Mass.)Article
- An adolescent rat model of vincristine-induced peripheral neuropathy.Neurobiology of pain (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Chemotherapeutic agents are widely used to treat patients with systemic cancer. The efficacy of these therapies is undermined by their adverse side-effect profiles such as cognitive deficits that have a negative impact on the quality of life of cancer survivors. Cognitive side effects occur across a variety of domains, including memory, executive function, and processing speed. Such impairments are exacerbated under cognitive challenges and a subgroup of patients experience long-term impairments. Episodic memory in rats can be examined using a source memory task. In the current study, rats received paclitaxel, a taxane-derived chemotherapeutic agent, and learning and memory functioning was examined using the source memory task. Treatment with paclitaxel did not impair spatial and episodic memory, and paclitaxel treated rats were not more susceptible to cognitive challenges. Under conditions in which memory was not impaired, paclitaxel treatment impaired learning of new rules, documenting a decreased sensitivity to changes in experimental contingencies. These findings provide new information on the nature of cancer chemotherapy-induced cognitive impairments, particularly regarding the incongruent vulnerability of episodic memory and new learning following treatment with paclitaxel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.